Labcyte Overview. Mark Fischer-Colbrie

Transcription

1 MOVING LIQUIDS with SOUND Labcyte Overview Mark Fischer-Colbrie 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S. and/or other countries.

2 Advances in Analysis Have Outpaced Sample Preparation Healthcare Research and Diagnostic Workflow Sample Collection Sample Prep Liquid Handling Detection and Analysis Billions have been invested in developing advanced analytical and detection tools Antiquated liquid handling has reached its physical limits and is a bottlenecj Urgent need for improved liquid transfer Precision Medicine needs precise liquid handling Achieving $1000 Genome (and going to $100 Genome) requires miniaturization of expensive reagents Biology is complex complexity requires more testing and lower cost per data point 2

3 Acoustic Dispensing Addresses ~$3B Market Positioned to disrupt existing markets / expand current markets Disrupting Enabling Automated Liquid Handling Robotics Manual Liquid Handling High / Mid Throughput Readers Genomics Biobanking / Tubes $640M $140M $600M $600M $540M $165M Echo Liquid Hander Access Workstation Echo Benchtop Echo-MS OEM / New Configurations Acoustic Tubes 3 $780M ~$2B

4 Labcyte Overview Precision liquid handling -- for the first time Established Invented touchless liquid handling using focused sound waves. - Digital acoustic dispensing - First Echo Liquid Handler Shipments Set up to be a global company to initially support global pharmaceutical firms Hundreds of Customers - 20 of top 20 pharmaceutical companies - Large and mid-size pharma, biotech, molecular diagnostics, genome centers, synthetic biology, precision medicine centers - Academic & research institutes - Contract research organizations Hundreds of Applications - Drug Discovery Precision Medicine - Genomics Molecular Diagnostics - Proteomics Mass Spectrometry Interface 4 Patents - 58 Issued US patents / multiple global patents from in-house inventions - Additional patent applications filed

5 Hundreds of Customers Worldwide 5

6 6 Numerous Prestigious Industry Awards Labcyte has received a number of awards from organizations like The R&D 100, The World Economic Forum, Ernst & Young, Frost & Sullivan, among others, who are recognizing the Company s impact Select Industry Awards Top 3 Life Science Company 2013 World Economic Forum 2015 Top 100 Global Companies (2013) 2007

7 Echo Acoustic LIQUID HANDLING The Future of Science is Sound Problems with Traditional Systems

8 Traditional Liquid Handling Issues Top Sources of Pipette Errors Human Errors Liquids Stick to Tip Viscosity Reduces Accuracy Immersed Tip Carry Over Liquid Surface Tension Reduces Accuracy Pipettes Take Up More Liquid Liquids Evaporate Liquid Temperature 55% 50% 44% 36% 28% 19% 8% 6% Labcyte Acoustic Droplet Ejection Eliminates the Top 6 Sources of Errors 8

9 Echo Acoustic LIQUID HANDLING The Future of Science is Sound A Sound Solution

10 Echo Liquid Handler in Action 10 Enter Title of Presentation Enter Date

11 Echo Acoustic LIQUID HANDLING The Future of Science is Sound The Labcyte System

12 Groundbreaking System Solution Innovative system centered around the transfer of precise amounts of fluids without contact Echo Liquid Handler Revolutionizes liquid handling by using acoustic energy to transfer liquids Labcyte Automation Incorporates Echo Liquid Handlers for complete workflow solution Enables Labcyte to own the sales process Labcyte Consumables Proprietary, acoustically qualified source plates Precise manufacturing and qualification process Echo Software Applications Array of applications that maximize the utility and flexibility of Echo Liquid Handlers 12

13 3 Global Commercial Organization Labcyte has been built with the vision to support global pharma from day one 52-person global field team -- sales, field applications, service and support Fully integrated field support team with a single CRM for all activities Europe Field Team Asia / Australia Field Team North America Field Team Direct Distribution Both Source: Company Management.

14 Extraordinary Momentum Across Applications Labcyte has experienced extraordinary momentum from industry-leading science publications. As of 2016, the Echo acoustic liquid handler has been featured in over 600 cumulative publications. Cumulative Publications 1 Journal of Laboratory Automation Special Issue on ADE Source: Company Management. Represents calendar year ending December 31, Highlights the impact of acoustic dispensing throughout research 600 Key topics include: Personalized Medicine Synthetic Biology Mass Spectrometry Interface Combination Screening Antibody Screening Genotyping Impact on High-throughput Screening 23 papers total Available at

15 Echo Acoustic LIQUID HANDLING The Future of Science is Sound Market / Application Spotlight

16 Broad Range of Applications Used in life sciences, research, drug discovery and personalized medicine Genomics Translational Drug Discovery Synthetic Biology Sequencing Epigenetics Gene Expression Precision Medicine HTS / Secondary Screening Cell-based Assays Biochemical Assays ADME-Tox Combination Screening Increase efficiency and speed while reducing costs Low cost, highly efficient library preparation Enabling highthroughput epigenetic screening Costeffective, highthroughput RT-qPCR From personalized medicine towards precision medicine Discover the right drugs with improved transfer performance Biologically relevant assays with unmatched data quality Simplify assay workflows with precise reagent transfers Enable costeffective, earlier safety screening Increase efficiency and speed while reducing costs Drug Discovery: Enabling miniaturization with unparalleled throughput and accuracy Cancer Research: Helping research programs drive down assay costs while enabling new experimental workflows - Result: New drugs discovered - Result: Patient sample drives therapy Genomic Research: Overcoming traditional barriers by dramatically reducing sample and reagent volume requirements Molecular Diagnostics: Eliminating cross-contamination and other data errors while dramatically reducing running costs - Result: Better experimental data at a fraction of the cost - Result: Lower operational costs (critical with reimbursement pressures) 16

17 Finds Drugs Missed by Traditional Systems AstraZeneca discovers cancer drugs with the Echo that would have been missed using traditional technologies Therapeutics would have been missed without the Echo AstraZeneca patent #7,718,653 presents data showing compounds ~10x 300x more potent using acoustics Pipette tips inhibited accurate drug effectivity analysis TABLE A Compound # Echo IC 50 (µm) Tecan Genesis IC 50 (µm)

18 Tips give the wrong answer. MedImmune study finds touchless acoustic transfer insures quality results for peptides The EC 50 value changes when the diluents are changed when using a pipette A Tip-based System The EC 50 value is constant when the Echo Liquid Handler is used B Echo System A changing concentratio n of BSA in the solution changes the apparent EC 50 when using a pipette A BRAVO BSA Curve Shift in rglp-1r No such shift is seen with the Echo system B Echo System BSA Curve Shift in rglp-1r 18

19 Comparison of Traditional vs. Echo Volumes Traditional: 20 µl Echo: 5 µl Reaction assembly gdna on Traditional: 8 µm gdna on Echo: 5 µm Primers: 625 nm Master Mix: 1x Type-It Fast SNP PCR (Qiagen) 19 Echo Liquid Handling for Genomics Labcyte Introduction

20 Genomics Product Positioning Next-generation Sequencing 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, and the Labcyte logo are registered trademarks or trademarks of Labcyte Inc.

21 Miniaturization in Genomics Application Cost per Reaction (at recommended) Miniaturized Cost per Reaction Volume Reduction (up to ) PCR / qpcr $0.27 $0.05 6X NGS Library Prep $72.91 $ X Sanger Sequencing $0.26 $0.06 5X MDA Setup $17.64 $4.41 4X Gibson/Golden Gate DNA Assembly $15.90 $ X Key Benefits Areas Impacted Use fewer tips Generate less waste Reduce cross-contamination Eliminate carryover errors Increase throughput Increase pool density / multiplex Synthetic Biology Cancer Research / Personalized Medicine Drug Discovery Academic Research Diagnostics 21 Echo Liquid Handling for Genomics Labcyte Introduction

22 Enabled Personalized Medicine Miniaturization and flexible combinations enable new applications: Institute of Molecular Medicine Finland (FIMM) Global leader in personalized medicine Real-time patient data decision making for treatment Repurposing cancer drugs with pharma Individualized system medicine - seminal advancement in cancer therapy Result Connecting patient testing at the cell level with genomic profiling Rescue extremely high risk patients Comprehensive data sets driving drug development and repurposing Pfizer renal cancer drug being re-purposed Only possible using acoustic liquid handling Initial work in blood cancers now being expanded into solid tumors This research opportunity is changing the way new drugs are introduced for patients: It is truly-game changing. Labcyte technology is a key platform for this next stage. Olli Kallioniemi, FIMM Director 22

23 Enabled Repurposing of Cancer Drugs Multiple findings in AML and CML treatment published in leading publications May 1, 2015 Novel drug candidates for advanced phase and blast crisis CML Three classes of drugs highly sensitive for most TKI resistant patient samples February 1, 2015 Joint development between FIMM and Pfizer Axitinib as a potential inhibitor to drug resistance Studied cancer cells from patients with CML and AML Study relied on FIMM s Drug Sensitivity and Resistance Testing (DSRT) methods Lead the way for proof-ofconcept clinical studies September 20, 2013 Identified potential new pathway for targeting AML treatment Conducted one or more combination screening of drugs using patient cells Had an impact on all patients treated Identified 3 drugs that may be considered for repurposing for AML purposes 23 The market availability of axitinib, (trade name Inlyta) means testing clinical utility for leukemia can be fasttracked

24 Enabled High-throughput Synthetic Biology Major improvements in cost and processing efficiency for microbial engineering Innovator in microbial engineering and screening technologies Renewable products: fuels, cosmetics, biopharmaceuticals Recent publication demonstrating significant NGS prep cost savings American Chemical Society, April 25, 2015 Illumina Nextera reagents were reduced 100-fold ($72 to 72 cents) Reduced time from 18 hours to 3 hours "By combining an Illumina MiSeq platform with a Labcyte Echo acoustic liquid dispensing system, we have developed a rigorous, low-cost QC method Elaine Shapland, Scientist 24

25 Case Study: Numerous expansion opportunities within existing customer base will continue to drive organic growth Progressive adoption of Echo Liquid Handler and Access workstation Compound management Protein Crystallography Cell based assays (HTRF) GMP Mouse tail genotyping 8 traditional systems replaced for one application These instruments are phenomenal when comparing them to traditional liquid handling robots - they are much faster, much more accurate and precise, and highly reproducible. The company is a pleasure to interact with and is structured in a collaborative manner that easily facilitates research and partnership projects. Colin Cox, Science Manager 25

26 Echo Acoustic LIQUID HANDLING The Future of Science is Sound Research and Development (announced)

27 Echo Acoustic LIQUID HANDLING The Future of Science is Sound Echo-MS

28 Echo-MS: Acoustic Mass Spec Interface High-throughput, low cost, label-free analysis Large pent up demand for improved sample prep and delivery systems for mass spectrometry Biopharma, government and academic accounts have limited adoption of MS based detection for high throughput needs due to performance and cost barriers Key benefits of MS detection for these customers include: Label free detection with multiple end point measurements Wide range of end points (Proteins, lipids, sugars, DNA) True high content read out enable pathway analysis and metabolomics 28

29 Echo-MS Successes Presented by AstraZeneca at SLAS and later ASMS Large reagent cost savings on a 1 million compound screen are extremely large. Traditional cost: $150,000 Acoustic MS Cost: $ times faster than fastest options Assay developed in 4 days as compared to usual time of 4 months Kinetic data acquisition enables assay optimization in 4 days instead of 4 months Major game changer in design of experiment False positives eliminated Z values at.70 All active hits were confirmed with LCMS 29

30 Echo Acoustic LIQUID HANDLING The Future of Science is Sound Acoustic Tubes and Instrumentation

31 Acoustic Tubes: Product Overview Labcyte s acoustic tube and instruments program delivers a solution to the unmet market need for fully acoustic workflows for small molecule and biologic storage Collaboration Overview Funding by AstraZeneca Partnership with Brooks New, 96 rackable acoustic storage tube as new recurring revenue source for Labcyte Development of updated Echo 555 platform for tube and plate dispensing AstraZeneca is completely revamping their tube storage system to take advantage of acoustic transfer 31

32 Questions? 2016 LABCYTE INC. All rights reserved. Labcyte, Echo, the Labcyte logo are registered trademarks or trademarks of Labcyte Inc., in the U.S. and/or other countries.